

The ARIA-EUFOREA Henning Løwenstein Research Award 2019

To a young scientist who has shown excellence within the field of allergy

Over the last few decades allergy has increased in prevalence to become the most common chronic disease in modern societies. The causes for this sudden change are not entirely clear, although they seem to be linked to 'modern lifestyle'.

For many years doctors have advised patients to avoid allergen exposure as a means of reducing symptoms; but recent research seem to indicate that there is no simple dose-response relationship between exposure and symptoms.

Pharmacotherapy is in widespread use all over the world to treat respiratory allergic disease. Although effective in controlling symptoms, pharmacotherapy does not change the course of disease and it does not prevent increases in prevalence.

It appears that allergy immunotherapy is the only treatment to treat the cause, induce immunological tolerance and to prompt disease modification. Disease modification implies long term effect, prevention of asthma in children with allergic rhinitis and prevention of new allergies.

In ALK we believe that reinforced efforts in research on the characteristics and treatment of respiratory allergic disease will lead the way for future achievements to the benefit of people with allergies all over the world.

The ARIA-EUFOREA Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy. The 2019 Award includes €20,000* and a travel grant to attend EUFOREA Forum (Research, Innovation and Education in Allergy and Airway Diseases) in Barcelona, Spain, 13th - 15th November 2019.

* If the winner is from a country where local legislation or medicolegal regulation prevents the transfer of monetary awards from the pharmaceutical industry to healthcare professionals, and in the case that the selected winner is a healthcare professional, the award is substituted by a travel grant or an educational grant of corresponding value. The grant is managed by ALK A/S and specified payment can only be given in the form of tickets or refund of tickets for a scientific or educational purpose, which is in agreement with the medicolegal regulation in that country. Accepted purposes could be transportation to a scientific congress or educational event, registration fees, educational charges or accommodation. ALK will ensure that each purpose is in agreement with the regulation in that particular country.

Application guidelines

The ARIA-EUFOREA Henning Løwenstein Research Award 2019

Scientists may apply for the ARIA-EUFOREA Henning Løwenstein Research Award of €20,000*.

- Applications must be concise, max. 2 pages including essential references, and should describe previous and current research activities.
- The applicant's precise role in these activities must be clearly stated.
- The applicant's curriculum vitae must also be enclosed, max. 2 pages.
- Applicants should be early in their academic career, within 10 years of their PhD (or equivalent degree), and should not be considered an established scientist, ie head of department, professor, etc.

**Please forward the application labelled "The ARIA-EUFOREA Henning Løwenstein Research Award 2019" to:
ALK A/S, Bøge Allé 6-8, DK-2970 Hørsholm, Denmark,
or preferentially by e-mail to: ARIA-EUFOREA-HLAWard@alk.net**

An International Scientific Board will evaluate the applications.

The members are:

Henning Løwenstein (Chairman), Denmark
Jean Bousquet, France *Lars K. Poulsen, Denmark*
Stephen Durham, United Kingdom *Harald Renz, Germany*
Peter Hellings, Belgium *Anne Tsicopoulos, France*

Deadline for applications: 31 August 2019





The ARIA-EUFOREA Henning Løwenstein Research Award 2019

Call for applicants

The ARIA-EUFOREA Henning Løwenstein Research Award is a biennial award given to a young scientist who has shown excellence within the field of allergy.

The winner will receive € 20,000* and will be offered a travel grant to attend the EUFOREA Forum (Research, Innovation and Education in Allergy and Airway Diseases) in Barcelona, Spain, 13th – 15th November 2019.

Scientists are invited to apply for the ARIA-EUFOREA Henning Løwenstein Research Award 2019.

ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Find more information at www.alk.net.

ALK A/S
Bøge Allé 6-8
DK-2970 Hørsholm
Denmark
Tel: +45 45 74 75 76
Fax: +45 45 74 86 90
www.alk.net

www.soeeborg.dk April 2019

